Moleculin Biotech, Inc.
NASDAQ Capital MarketTotal Valuation
Moleculin Biotech, Inc. carries a market capitalization of 11.47M, placing it among publicly traded companies globally. Its enterprise value stands at -5.23M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 11.47M |
| Enterprise Value | -5.23M |
Share Statistics
Moleculin Biotech, Inc. currently has 5.34M shares outstanding.
| Shares Outstanding | 5.34M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.02 |
| P/TBV Ratio | 1.18 |
| P/FCF Ratio | -0.20 |
| P/OCF Ratio | -0.20 |
Financial Position
Moleculin Biotech, Inc. maintains a current ratio of 1.38, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.38 |
| Quick Ratio | 1.30 |
| Debt / Equity | 2.15 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -136.70 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 12.39 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Moleculin Biotech, Inc.'s stock has declined approximately -89.28215% over the past 52 weeks. The 50-day moving average sits at 2.53, while the 200-day moving average is 4.93.
| Beta (5Y) | N/A |
| 52-Week Price Change | -89.28215% |
| 50-Day Moving Average | 2.53 |
| 200-Day Moving Average | 4.93 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -26.97M, while operating income came in at -27.03M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -27.03M |
| Pretax Income | -30.33M |
| Net Income | -30.33M |
| EBITDA | -26.97M |
| EBIT | -27.03M |
| Earnings Per Share (EPS) | -14.59 |
Balance Sheet
Moleculin Biotech, Inc. holds 10.32M in cash and equivalents against 326,000.00 in total debt, resulting in a net debt position of -10.32M. Total book value stands at -218.84M, with working capital of 3.00M providing operational flexibility.
| Cash & Cash Equivalents | 10.32M |
| Total Debt | 326,000.00 |
| Net Debt | -10.32M |
| Equity (Book Value) | -218.84M |
| Book Value Per Share | -105.25 |
| Working Capital | 3.00M |
Cash Flow
Moleculin Biotech, Inc. produced -24.28M in operating cash flow over the past twelve months.
| Operating Cash Flow | -24.28M |
| Capital Expenditures | N/A |
| Free Cash Flow | -24.28M |
| FCF Per Share | -11.68 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -564.89 |
| FCF Yield | -509.97 |
Stock Splits
Moleculin Biotech, Inc.'s most recent stock split took place on December 1, 2025 with a 25:1 split ratio.
| Last Split Date | 12/1/2025 |
| Split Ratio | 25:1 |
Scores
Moleculin Biotech, Inc. posts an Altman Z-Score of -31.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -31.74 |